Side Effects of OCP (Oral Contraceptive Pill)

Cardiovascular Effects

• Thromboembolic disease - the most serious risk. Estrogen stimulates hepatic synthesis of clotting factors and increases platelet aggregability. Thromboembolism risk is greatest in smokers over 35 years of age.
• Hypertension - seen in ~5% of users, especially those with pre-existing hypertension. Lower with newer low-dose preparations.
• Lipid effects - progestins tend to raise LDL and lower HDL; estrogens do the opposite. Modern low-dose pills generally do not produce unfavorable lipid profiles, though slight triglyceride elevation is possible.
• Migraine - risk of stroke with combined OCP in women who have migraine with aura.

Metabolic and Endocrine Effects

• Early high-dose pills impaired glucose tolerance; current low-dose preparations may actually improve insulin sensitivity.
• Estrogen component increases hepatic synthesis of binding proteins for thyroid hormones, glucocorticoids, and sex steroids - this can affect interpretation of endocrine function tests.
• Increased risk of gallbladder disease (weak association, mainly in current or very long-term users).

GI and Hepatic Effects

• Nausea and vomiting - common early side effect, usually transient.
• Hepatic adenoma and hepatocellular carcinoma - approximately 2-fold increased risk of liver cancer after 4-8 years of use, but these are rare cancers and absolute increases are small.
• Cholestasis (rare).

Breast and Reproductive Effects

• Breakthrough bleeding / irregular spotting - especially in early cycles.
• Breast tenderness - due to estrogenic effect.
• Small increase in breast cancer relative risk (1.1-1.2x) in current users of childbearing age. Importantly, 10 years after stopping, there is no difference vs. never-users. Cancers diagnosed in users tend to be more localized.
• Cervical cancer - ~2-fold increased risk only in long-term users (>5 years) with persistent HPV infection.

Protective / Beneficial Effects (Worth Noting)

• Reduces endometrial cancer by ~50% (lasts 15 years after stopping).
• Reduces ovarian cancer incidence.
• Likely reduces colorectal cancer risk.
• Reduces dysmenorrhea, menorrhagia, and pelvic inflammatory disease.

CNS / Mood

• Headache, mood changes, decreased libido reported in some users.
• Interaction with St. John's Wort - reduces OCP efficacy.

Diagnostic Criteria for PCOS (Polycystic Ovary Syndrome)

Three Major Criteria Sets

1990 NIH Criteria (BOTH must be present)

1. Chronic anovulation
2. Clinical and/or biochemical signs of hyperandrogenism + exclusion of other etiologies

2003 Rotterdam Consensus Criteria (2 out of 3 required) - Most Widely Used

1. Oligoovulation or anovulation (oligomenorrhea or amenorrhea)
2. Clinical and/or biochemical signs of hyperandrogenism
3. Polycystic ovaries on ultrasound + exclusion of other etiologies (congenital adrenal hyperplasia, androgen-secreting tumors, Cushing syndrome)

PCOS is a diagnosis of exclusion - other disorders mimicking it must be ruled out first.

Four Rotterdam Phenotypes

Ultrasound Criteria for PCO Morphology

• ≥20 follicles in either ovary measuring 2-9 mm in diameter, AND/OR
• Increased ovarian volume (>10 mL)
• A single ovary meeting the criteria is sufficient.

Note: PCO appearance alone is found in ~23% of reproductive-age women. Only a fraction of these have the full clinical syndrome of PCOS (prevalence 5-10%).

Clinical Features of Hyperandrogenism

• Hirsutism (most common - ~70% of PCOS in the US)
• Acne
• Male-pattern alopecia
• Biochemical: elevated free/total testosterone, elevated DHEAS

Minor Diagnostic Criteria (less consistent)

• Elevated LH:FSH ratio
• Insulin resistance (IR)
• Perimenarchal onset of hirsutism
• Obesity (present in >50% of PCOS patients; central/android distribution)

Conditions to Exclude (Differential Diagnosis)

• Hyperprolactinemia
• Non-classic congenital adrenal hyperplasia (measure basal 17-OHP)
• Cushing's syndrome
• Androgen-secreting neoplasm
• Thyroid disorder
• Hypo/hypergonadotropic disorders

PCOS Diagnostic Algorithm

Associated Metabolic Risks (Workup Indicated)

• ~1/3 of obese PCOS patients have impaired glucose tolerance; 7.5-10% have type 2 DM
• Increased cardiovascular risk (check fasting lipids)
• Obstructive sleep apnea
• Endometrial carcinoma risk (from chronic unopposed estrogen due to anovulation)
• Depression screening (PHQ-2)

About Your Diagnosis - Is It Really PCOS?

Rotterdam Criteria (the standard used globally)

1. Oligomenorrhea/anovulation (irregular periods)
2. Clinical or biochemical hyperandrogenism (hirsutism, acne, elevated testosterone)
3. Polycystic ovarian morphology on USG

The Key Point

An ultrasound showing polycystic ovarian appearance is found in about 23% of all reproductive-age women - but only 5-10% actually have PCOS. An English study confirmed that a PCO appearance alone, without symptoms, is not associated with impaired fertility or fecundity.

• Berek & Novak's Gynecology

What You Should Do

• Testosterone levels (free and total)
• LH:FSH ratio (elevated LH suggests true PCOS)
• Fasting insulin and glucose (to check insulin resistance)
• Prolactin, TSH (to rule out other causes)
• AMH (anti-Mullerian hormone - reflects follicle count)

What is Insulin Resistance?

• High circulating insulin levels (hyperinsulinemia)
• Eventually, blood sugar starts rising (pre-diabetes, then type 2 diabetes)

How it connects to PCOS

Insulin resistance → Hyperinsulinemia → Ovarian androgen overproduction → Irregular ovulation + Hyperandrogenism

Signs that might suggest insulin resistance even without obvious PCOS symptoms:

• Dark, velvety skin patches at the neck/armpits/groin (acanthosis nigricans)
• Weight gain around the belly
• Fatigue after carb-heavy meals
• Craving sweets constantly

Latest Guidelines on PCOS Diagnosis (2023 International Evidence-Based Guideline)

Core Diagnostic Rule (Still 2 out of 3 - Rotterdam Backbone)

Key update in 2023: Anti-Mullerian hormone (AMH) can now be used as an alternative to ultrasound for criterion 3 in adults. This is a new addition not in previous guidelines.

What the 2023 Guideline Says About Ultrasound-Only / Asymptomatic Cases

Ultrasound Criteria (Updated Thresholds)

Note: The 2003 Rotterdam criteria used ≥12 follicles. The threshold was later raised to ≥25, and the 2023 guideline now sets it at ≥20. If your USG used the old ≥12 cutoff, the finding may not even meet modern criteria.

The Critical Practice Points (Direct Quotes from 2023 Guideline):

PP 1.4.9: "In patients with irregular menstrual cycles and hyperandrogenism, an ovarian ultrasound is NOT necessary for PCOS diagnosis."

PP 1.4.6: "There are no definitive criteria to define PCOM on ultrasound in adolescents; hence, it is NOT recommended in adolescents."

The guideline explicitly states: "Where irregular menstrual cycles and hyperandrogenism are present, diagnosis is simplified and ultrasound or AMH are NOT required for diagnosis."

What this means for you:

The Systematic Review on USG Accuracy (2024)

• Analyzed 31 studies, 3,883 controls vs. 3,859 PCOS patients
• FNPO = best single marker (sensitivity 84%, specificity 91%, AUC 0.905)
• The meta-analysis could NOT determine a single definitive cutoff due to heterogeneity across geographic regions - Asian studies showed different diagnostic accuracy than European or North American ones
• Significant geographical variation: BMI, age, ethnicity affect what "polycystic morphology" means

For Adolescents Specifically

• Ultrasound should not be used for PCOS diagnosis in adolescents (poor specificity - many teens normally have multi-follicular ovaries)
• In adolescents, both hyperandrogenism AND ovulatory dysfunction are required
• AMH also not recommended for adolescent diagnosis

Bottom Line for Your Case

1. USG showing polycystic morphology alone = NOT a PCOS diagnosis. Full stop.
2. You need at least one more criterion - either hyperandrogenism (blood tests for testosterone, clinical signs) OR confirmed anovulation (not just slightly irregular periods).
3. A 2-3 day irregularity in cycle length is within normal variation and does not constitute oligomenorrhea (which means cycles >35 days or <8 cycles/year).
4. The gynecologist should have ordered blood tests (free testosterone, LH/FSH, AMH, insulin, TSH, prolactin) before diagnosing you.
5. If only an ultrasound was done, the diagnosis is not evidence-based per current guidelines.